Sign up
Pharma Capital
Market: ASX
52-week High/Low: A$0.58 / A$0.35
Sector: Pharma & Biotech
Market Cap: A$28.74M

Cellmid Ltd (ASX:CDY) is listed on the Australian Securities Exchange.

Cellmid Ltd

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Cellmid Ltd

Cellmid Ltd Snapshot

Cellmid Limited (ASX:CDY) is an Australian biotechnology company developing first in class antibodies against the novel target midkine (MK). 

Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the growth factor midkine (neurite growth-promoting factor 2). Midkine is an extensively validated therapeutic and diagnostic target in cancer, inflammation and auto-immune disorders. 

Cellmid is actively seeking partners to commercialise these significant intellectual property assets in cancer, ischemia, and inflammatory diseases.

Midkine ELISA

The Cellmid MK ELISA is a fully validated GMP manufactured and CE marked highly sensitive sandwich enzyme immunoassay in a 96 well plate format. The supplied plate is pre-coated with a monoclonal antibody specific to MK and is in a ready-to-use state. The detector antibody is a biotin-conjugated second monoclonal antibody specific for midkine. 

(click here for more information)

Advangen International Hair Loss Products

Advangen International is a wholly owned subsidiary of Cellmid that develops and sells scientifically validated treatments for various forms of hair loss (alopecia). Developed from Japanese scientific research, Advangen’s products have a well understood mechanism of action and they have been proven to work by independent scientific testing. Advangen’s discovery and product development processes are the same ones used to identify and test new medicines for treating human disease.

(click here for more information)

Evolis Tonic for men and women

Évolis is a range of TGA listed hair growth products, the result of over 12 years of research and development. The ingredients in Évolis have been extensively tested for safety and efficacy.

In independent clinical trials 74% of the study participants have had increased hair growth and reduced hair loss*.

(click here for more information)

Last updated 7th June 2016.

Dr David King

Dr David King brings a depth of corporate governance, capital markets and listed company board experience to Cellmid. He has previously held positions as Executive Director, Chief Executive Officer and Managing Director in a number of private and listed companies.

An expert in high growth companies Dr King has a track record in starting business ventures and developing them into attractive investment and/or take-over targets. His experience in successful start-up businesses has been instrumental in Cellmid’s acquisition of the midkine intellectual property portfolio.

Dr King is a Fellow of the Australian Institute of Company Directors, a Fellow of the Australian Institute of Geoscientists and the Australian Institute of Mining & Metallurgy (Chartered Professional, Management) and holds degrees in physics and geophysics and a PhD in Seismology from the Australian National University

Ms Maria Halasz
Managing Director and Chief Executive Officer

Maria Halasz has been involved with biotechnology companies for over 22 years; initially working in executive positions in biotechnology firms, then managing investment funds and later holding senior positions in corporate finance specialising in life sciences.

Since taking over as Chief Executive and Managing Director of Cellmid Maria has led the restructure of the business, the acquisition of the midkine and Advangen intellectual property portfolios and the recapitalisation of the company. An accomplished public company CEO with international experience Maria has executed transactions in the US, China, Europe, Japan and the UK.

Maria is a graduate of the University of Western Australia (B.Sc., MBA) and the Australian Institute of Company Directors. She has board experience in public and private companies, and has acted on advisory boards of non-profit organisations.

Mr Bruce Gordon
Non-Executive Director

A seasoned audit partner and corporate finance specialist, Bruce Gordon is an experienced finance professional with a career spanning more than 35 years’ advising and providing financial services to private and publicly listed companies as well as subsidiaries of large multinationals.

Formerly lead partner of the BDO Australia National Corporate Finance Team and the BDO East Coast Partnership Corporate Finance Team he presently holds a number of directorships and senior financial consulting positions.

An experienced auditor and corporate adviser to ASX listed companies, Bruce is also experienced in accounting and compliance in overseas capital markets. Renowned as an energetic business developer and marketer, Bruce has a formidable network of contacts in ASX listed companies across multiple sectors. He is a Fellow of Chartered Accountants Australia and New Zealand, and a Fellow of the Australian Institute of Company Directors.

Dr Fintan Walton
Non-Executive Director

Dr Fintan Walton is Founder and CEO of PharmaVentures Ltd, a UK based corporate advisory firm with more than 30 professional advisers, assisting pharmaceutical and biotechnology companies worldwide in all aspects of corporate transactions, business brokering, mergers and acquisitions and licensing deals. Since he founded PharmaVentures in 1992, he and his team have advised blue chip clients in North America, Europe and Asia, delivering more than 700 assignments for 180 companies in 38 countries.

Dr Walton has worked with clients including most of the major and mid-sized pharmaceutical and biotechnology companies. His experience extends to industries such as pharmacetuicals, diversified chemicals, diagnostics, medical devices, generic and over-the-counter medicines as well as government agencies. He has transactional experience representing corporates as well as major banks, investment and merchant banks, private equity and venture capital groups.

Educated at Trinity College (Dublin, Ireland), where he obtained his PhD in genetics, Dr Walton has subsequently gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992) prior to founding PharmaVentures.

Mr Koichiro Koike
Managing Director, Advangen Inc.

Koichiro (Ko) Koike has over 27 years of experience working in cross border business development roles for a number of Australian and Japanese healthcare companies and brings strong strategic and corporate development skills to Cellmid.

Based in Melbourne for 15 years, Ko initiated and took charge of numerous transactions including the arrangement of product development and distribution in Japan involving two of Australia's sleep medicine companies, Resmed and Compumedics.

He played a key role in Cellmid’s acquisition of the midkine asset portfolio and later the acquisition of Advangen Inc, where he was appointed Managing Director. He has since expanded the business in Japan and internationally successful negotiating multiple distribution agreements. Ko graduated from Tokyo University of Foreign Studies with BA. He lives in Tokyo, Japan.

Ms Aliceson Rourke
Chief Financial Officer & Company Secretary

Aliceson Rourke is an experienced Chartered Accountant with over 10 years of experience as Chief Financial Officer and Company Secretary across a wide range of industry sectors.

She has extensive experience in all aspects of public company finance, administration and governance including listings on the Australian Stock Exchange, public capital raisings, capital restructures, mergers and acquisitions.

She has previously held positions as Executive Director, Chief Financial Officer and Company Secretary for a number of private and listed companies.

Mr Dominic Dang
Financial Controller

Dominic has over thirty years of commercial accounting experience. He has previously held position as Financial Controller for a number of diversified private companies.

Dominic has been a Director at Iszac Pty Ltd since 2009, an accounting consultancy serving a number of corporate clients. He is a Fellow Member of the Institute of Public Accountants.

Last updated 7th June 2016.

Cellmid Limited

Suite 1802, Level 18
15 Castlereagh Street
Sydney NSW 2000

Telephone : +61(0)2 9221 6830
Fax : +61(0)2 9221 8535



Level 7, 207 Kent Street
Sydney NSW 2000

Telephone: +61 2 9290 9600
Facsimile: +61 2 9279 0664

View full CDY profile View Profile
View All

Executive video interviews


© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.